Bristol-Myers Squibb (BMY) Tops Q2 EPS by 3c; Raises Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. ZETA
9. DAL
10. TMUS

Go back to Bristol-Myers Squibb (BMY) Tops Q2 EPS by 3c; Raises Outlook

Bristol-Myers Squibb Reports Second Quarter Financial Results

July 28, 2016 6:59 AM EDT

Increases Second Quarter Revenues 17% to $4.9 Billion Posts Second Quarter GAAP and Non-GAAP EPS of $0.69 Achieves Important Regulatory Milestones in Immuno-Oncology Opdivo + Yervoy Regimen Approved in Europe for Metastatic Melanoma Opdivo Approved in the U.S. for the Treatment of Classical Hodgkin Lymphoma Opdivo Granted Breakthrough Therapy Designation for Advanced Form of Bladder Cancer Empliciti Approved in Europe for Combination Treatment for Multiple Myeloma... More